Abeona Therapeutics Inc. (NASDAQ:ABEO) has been given a consensus rating of “Buy” by the six ratings firms that are covering the company. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $16.80.

Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 18th. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research note on Friday, September 23rd. Maxim Group restated a “buy” rating and issued a $14.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 18th. Finally, FBR & Co restated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 26th.

Abeona Therapeutics (NASDAQ:ABEO) opened at 6.45 on Thursday. Abeona Therapeutics has a 52 week low of $2.05 and a 52 week high of $9.44. The firm has a 50 day moving average of $6.63 and a 200-day moving average of $4.12. The company’s market capitalization is $216.37 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, analysts forecast that Abeona Therapeutics will post ($0.74) earnings per share for the current year.

In other news, Director Todd Wider acquired 5,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, September 20th. The shares were purchased at an average cost of $5.48 per share, for a total transaction of $27,400.00. Following the completion of the purchase, the director now directly owns 75,000 shares of the company’s stock, valued at approximately $411,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 13.00% of the company’s stock.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Geode Capital Management LLC raised its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 16.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,496 shares of the biopharmaceutical company’s stock after buying an additional 10,082 shares during the period. Geode Capital Management LLC owned 0.22% of Abeona Therapeutics worth $180,000 as of its most recent filing with the SEC. 19.96% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.